Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14867079 | 0.80 | BRD4 (0.44) | GRM5GSK3BPDE3BPDE3AGSK3A | |
| SCHEMBL828633 | 0.77 | GSK3B (0.36) | GSK3BPDE3BPDE3AGSK3ACDK5 | |
| SCHEMBL21144746 | 0.76 | GRM5 (0.60) | GRM5 | |
| SCHEMBL2603742 | 0.75 | BRD4 (0.49) | BRD4 | |
| SCHEMBL6124130 | 0.74 | GRM5 (0.42) | GRM5 | |
| SCHEMBL2233893 | 0.71 | NPC1 (0.50) | GSK3BPDE3BPDE3AGSK3ACDK5 | |
| SCHEMBL30493623 | 0.71 | NPC1 (0.50) | GSK3BPDE3BPDE3AGSK3ACDK5 | |
| SCHEMBL17881393 | 0.70 | BRD4 (0.54) | GSK3BPDE3BPDE3AGSK3ACDK5 | |
| SCHEMBL22049622 | 0.70 | PDE2A (0.44) | GSK3BPDE3BPDE3AGSK3ACDK5 | |
| SCHEMBL13999790 | 0.70 | MAPK1 (0.39) | GRM5BRD4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-01 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, BDKRB2 | GRM5 109/4885XIAP 2704/4885BIRC2 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.